Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/bJIhSwMvwx8/nature-biotechnology-california-stem.html

Roman Reed, a Fremont, Ca., patient advocate, this week was named Stem
Cell Person of 2012 by the Knoepfler Stem Cell Lab at UC Davis, which
cited Reed for energizing a new generation of
advocacy.

Roman Reed (left) and Paul Knoepfler Knoepfler Lab photo

“One of the most notable was
catalyzing the TJ Atchison Spinal Cord Injury Research Act in
Alabama, which provides $400,000/year in funding for research. Of
course, TJ and many others who helped make this possible also deserve
great credit and have my admiration, but Roman provided key
leadership. Here in California, Roman’s Law supported its 11th
year of grants all eligible for all forms of stem cell research.
Roman informs me that it funded $749,00 overall and approximately
$200,000 in stem cell funding. 

“In addition, Roman in 2012 mentored
and energized a whole new generation of advocacy from young,
energetic leaders: TJ Atchison, Katie Sharify, Richard Lajara
and Tory Minus.”

Leigh Turner U of Minn photo

“Only 6% behind Roman was the amazing
activist Ted Harada followed by Roman’s dad the remarkable Don
Reed, the wonderful Judy Roberson, and the super Katie Sharify nearly
all tied for third. Next after them was the relative new kid in stem
cell town, Leigh Turner.”

“Leigh took the courageous,
outside-the-box step in 2012 of contacting the FDA to investigate
Celltex when he perceived patients could be at risk. As “thanks”
for his action, he was put under enormous pressure and there was talk
of possible litigation against him. Pressure was applied to his
employer, the University of Minnesota. We’ll never know for sure,
but from everything that I know I believe that Leigh’s actions
directly led to prompt FDA action, which otherwise might not have
happened at all or until much later. In my opinion, Leigh’s act of
courage, helped make hundreds of patients safer in a direct way and
indirectly may have set a higher standard for the field of stem cell
treatments.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/QfG7CijBsy4/roman-reed-is-stem-cell-person-of-2012.html

The stock price of Biotime, Inc., of
Alameda, Ca., shot up more than 12 percent today following the
announcement of a complex deal that will give it the stem cell assets
of Geron Corp., the first firm to launch a clinical trial for an hESC
therapy.

Geron stock price Jan. 2-8 Google chart

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/mQRu0qUrqwM/biotime-stock-jumps-22-percent-in-two.html

Geron Corp., which pioneered the first
clinical trial of an hESC therapy, today sold its stem cell
business to another San Francisco Bay Area firm whose two top
executives were once CEOs at Geron.

Michael West BioTime photo

Tom Okarma Geron photo

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/TBbR-z7OPWc/biotime-buys-gerons-stem-cell-assets.html

Stem cells are rarely the subject of
cartoons, but one popped last week from Bizarro.

“To use a term common in the
vernacular of geneticists, it’s creepy cool.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/gXXLRtG2Sx4/reverse-engineering-grandpa.html

AsiaOne

Dr Koh to scale back on medical practice if elected in Punggol East AsiaOne He is also a part-time Consultant Surgeon at the Department of Colorectal Surgery in Singapore General Hospital (SGH), and remains as the Acting Director of the Colorectal Cancer Molecular Genetics Research Laboratory. "I think it's inevitable, that's ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHtScQg1JMqP1mFE9KryfR_TGCn5w&url=http://www.asiaone.com/News/Latest%252BNews/Singapore/Story/A1Story20130113-395191.html

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/dd7jnv/stem_cell_therapy) has announced the addition of the "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity" report to their offering.

Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Stem Cell Research in Asia-Pacific a Growth Engine for Region's Scientific Ambitions

The stem cell therapy market in Asia-Pacific is poised to offer significant contributions in the future, thanks to renewed interest by the respective governments of India, China, Japan, South Korea and Singapore to provide cures for a range of diseases, states a new report by healthcare experts GBI Research.

Stem cells are unique body cells that possess the ability to divide and differentiate into diverse cell types, and can be used to produce more stem cells. The use of adult stem cells has been successfully employed to treat bone and blood related disorders such as leukemia, through bone marrow transplants. Stem cell therapy is used to repair and regenerate the damaged tissue, though the actual mechanism of action is largely unknown.

The growth in the stem cell therapy market will not only provide treatment options but will also contribute significantly to the countries' Gross Domestic Product (GDP), with the President of South Korea only last year referring to stem cell research as a new growth engine for the nation's economy. In order to support the stem cell industry, regulatory guidelines in Asia-Pacific countries allow stem cell research, and this has led to its commercialization. India and South Korea are the leaders in the commercialization of stem cell therapy, with approved products for Acute Myocardial Infarction (AMI), osteoarthritis and anal fistula in Crohn's disease, amongst others. The countries allow the use of human embryonic stem cells and provide adequate funding support for the research.

Stem cell therapy is an emerging field, and a large amount of research is currently being carried out by institutions such as hospitals, universities and medical colleges. According to GBI Research's analysis of the stem cell therapy research in Asia-Pacific, 63% of pipeline molecules were being researched by academia. The emergence of institutional research has boosted stem cell discoveries, as companies can be put off conducting research due to uncertain therapeutic outcomes. China and Japan witness only a negligible industry presence in stem cell research, as academic institutions dominate - however in contrast, India has the presence of both industry and academia. The major institutions engaged in stem cell research in India are LV Prasad Eye Institute (LYPEI) for Limbal Stem Cell Technology (LSCT), and the Post Graduate Institute of Medical Education and Research (PGIMER) for stem cell therapy for type 2 diabetes mellitus.

The market is poised for significant growth in the future, due to the anticipated launch of JCR Pharmaceuticals' JR-031 in Japan in 2014, and FCB Pharmicell's Cerecellgram (CCG) in South Korea in 2015. GBI Research therefore predicts that the stem cell therapy market will grow in value from $545m in 2012 to $972m in 2018, at a Compound Annual Growth Rate (CAGR) of 10%.

Companies Mentioned

Read more:
Research and Markets: Stem Cell Therapy Market in Asia-Pacific to 2018

Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3
Stem cell therapy for osteoarthritis using adipose (fat) stem cell. Case study of 76 year-old man with osteoarthritis in his knees. Stromal vasular fraction treatment statistics including side effects collected over 800 infusions. Stem cell treatments for sports injuries and why pro sports stars are seeking treatment. Case study of a professional dancer with knee and neck problems who returned to competition after stem cell treatment in Panama.

By: cellmedicine

Go here to see the original:
Jorge Paz MD: Adult Stem Cell Therapy for Arthritis, Sports Injury, and Autoimmune Disease || 3 of 3 - Video

By JENNY F. MANONGDO

Manila, Philippines Doctors yesterday warned against fatal complications of the use of stem cell therapy.

According to the Philippine Society for Stem Cell Medicine (PSSCM), a stem cell transplant poses a host of complications, including fatal complications that depend on several factors such as the type of blood disorder, type of transplant and the age and health of the person receiving the transplant. If the stem cell that you received is not from your own body, it could lead to fatal complications, PSSCM said.

The Philippine Medical Association (PMA) also warned that a patients body may reject the transplant stem cells from a donor.

Although some people experience few problems with a transplant, others may develop complications that may require treatment or hospitalization. Some complications could even be life-threatening, said Dr. Leo Olarte, PMA vice-president.

According to Olarte, the complications that can arise with a stem cell transplant include graftversus-host disease, stem cell (graft) failure, organ injury, infections, cataracts, infertility, new cancers, and even death.

According to Olarte, a person who will undergo a stem cell transplant from a donor (allogeneic stem cell transplant) may be at risk of graft-versus-host disease.

This condition occurs when a donors transplanted stem cells attack your body. Graft-versushost disease can be mild or severe. It can occur soon after your transplant or months to years later. Aside from the graft-versushost disease, stem cell transplant from a donor can likewise affect any organ, commonly the skin (rash, often like sunburn), gut (mouth sores, abdominal pain, diarrhea, nausea or vomiting), liver (jaundice or yellowing of the skin), lungs (blocked airways) or eyes (irritation and light sensitivity).

Olarte said it could also lead to chronic disability arising from organ injury or infections that are potentially life-threatening.

Commercial establishments offering stem cell treatments have increased following its popularity in the treatment of various diseases.

Continue reading here:
DOH: Stem cell therapy dangerous

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4gllbg/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 285 of these are profiled in part II of the report along with tabulation of 272 alliances. Of these companies, 156 are involved in stem cells. Profiles of 70 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 11 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

Originally posted here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - 2013 Report

REHOBOTH, Mass. --

A first of its kind procedure is being performed in Massachusetts Monday. Its a stem cell therapy on a dog.

"He can't get comfortable, can't lay down, because of the pain, so he sits up and stares at the wall all night, which is tough to watch," said Bob Cook, Bubbas owner.

Cook of Taunton is talking about his 2-year-old English Bulldog Bubba, who suffers from hip dysplasia.

He said his condition has gotten worse in the last several months. After doing research, he found out about a regenerative stem cell therapy and has been hopeful.

He brought Bubba to the Abbot Animal Hospital in Rehoboth.

"Hopefully we can give these animals relief and increase quality of life and their life span as well, said Dr. Ashraf Gomaa.

Gomaa is the only doctor in our area certified by MediVet America, the company that developed this technology.

After extracting fat from Bubba, it is processed in a machine that basically breaks down the cells to get to the healthy stem cells. The cells are then injected back into Bubba into the area of concern.

"Replacing the bad cells with new cells, pretty advanced technology," Gomaa said.

See the original post here:
Owner hopes stem cell therapy will get dog's life back

AUSTIN, Texas, Jan. 8, 2013 /PRNewswire/ --On Friday, January 4th Celling Biosciences hosted the Austin Cell Therapy Symposium at the downtown Hilton to build awareness and provide a platform for physicians, scientists, policy makers and academia to discuss the impact of cell therapy on global healthcare and the opportunity for the local community in Central Texas. Cell therapy will revolutionize the landscape of medicine by providing viable and affordable treatment options across all disciplines of medicine without the controversy associated with embryonic stem cells.

The keynote speaker for the event was Dr. Arnold I. Caplan, Professor of Biology and Director of the Skeletal Research Center at Case Western Reserve University. Dr. Caplan has published over 390 papers and manuscripts and has long been supported by the National Institute of Health and other non-profit and for-profit agencies for his efforts in trying to understand the development, maturation and aging of cartilage, bone, skin and other mesenchymal cell tissues."I firmly believe that the research and development efforts going on today will change the future of medicine forever. We are only scratching the surface of the potential there is to treat different health issues with cell therapy. It takes a concerted effort by scientists, physicians and commercial entities for patients to ultimately enjoy the benefits. This type of platform provided by Celling Biosciences allows us to effectively progress forward," says Dr. Caplan.

Dr. Carl Gregory from the Texas A&M Regenerative Medicine Institute and Dr. Vivienne Rebel from UT Health Science Center San Antonio both represented local academia in Central Texas. The research being conducted and the recruitment of students trained in these programs are obvious reasons for Texans to keep supporting Governor Perry's efforts to make Texas a leader in the research and commercialization efforts of regenerative cell therapy. Both speakers are leading efforts for research that will one day lead to alternative healthcare options.

Dr. Philippe Hernigou, a leading orthopedic surgeon from France, presented his 20 years clinical experience working with cell therapy in his practice as University of Paris Chief of Orthopedics.Dr. Hernigou is well published in his clinical use of cell therapy and has treated over 2,500 patients utilizing autologous bone marrow derived cells to treat a wide range of orthopedic pathologies. Dr. Hernigou's research on the safety of cell therapy has been accepted and will be presented at the 2013 AAOS, a leading congress for orthopedic surgeons.

Clinicians were also represented by Dr. Scott Spann, an orthopedic surgeon at Westlake Hospital in Austin, who provides care to patients with spinal cord injury.Dr. Spann believes one day cell therapy will be a common option for patients suffering from debilitating health issues like spinal cord injury.A member of the audience and orthopedic surgeon, Dr. Christoph Meyer has been utilizing cell therapy in his practice for years and also believes it is the future of medicine. "Thanks to these efforts, physicians are benefiting from access to the growing body of research based medicine being established in the field of cellular therapy and regenerative medicine.As the technology is developed, it ultimately gives my patients the best care available and this event gives me the opportunity to discuss experiences with world leaders in cell therapy."

Healthcare is going through major changes and cell therapy is going to have many challenges ahead. Julian Rivera, legal healthcare specialist at the Brown McCarroll Law Firm, discussed the impact of the recent challenges in front of the Texas Medical Board which has adopted rules that work with the FDA to help keep Texas revolutionizing cell therapy.Mr. Rivera believes that the legal issues will take time but is optimistic about how the State of Texas has handled the challenges thus far.

"We are fortunate to have industry leaders joining us to discuss the future impact of cell therapy. We are proud to be Texans who are pioneering the way in the global healthcare market place for regenerative cell therapies. Celling Biosciences understands that the cell therapy market is in its infancy which is a key reason why we invest heavily on research and development with our teams of scientists, engineers and registered nurses providing physicians with proven cell centric technologies and techniques that collectively help to recreate the human body's biological environment. It is not about just providing cells to treat patients.We believe with the help of these thought leaders presenting today we will get closer to better understanding how to keep delivering safe, efficacious and cost effective therapies to patients," says Founder and CEO of Celling Biosciences, Kevin Dunworth.

About Celling BiosciencesCelling Biosciences is an Austin based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine.Celling's product-offering focuses on autologous adult stem cell therapy and the devices and services that compliment these procedures.For more information please visit: http://www.cellingbiosciences.com.

Read more:
Celling Biosciences Hosts Austin Cell Therapy Symposium

AMSTERDAM, January 7, 2013 /PRNewswire/ --

Official journal of the International Society for Cellular Therapy (ISCT) to be published by Elsevier beginning January 2013

Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to announce that the International Society for Cellular Therapy (ISCT) has selected Elsevier to publish Cytotherapy: The Journal of Cell Therapy effective January 2013.

"Elsevier presented ISCT with unsurpassed reach into the global medical community, top class publishing services, and significant experience in this field. We are extremely confident that our collaboration with Elsevier will not only help Cytotherapy grow for the benefit of our members and readers, but also for the benefit of all scientists, technologists, regulators, manufacturing experts and others dedicated to translational development of safe and effective cell therapies," said ISCT President, Kurt Gunter, MD, FASCP.

Cytotherapy is a highly influential publication in the mainstream of the rapidly expanding field of cell-based treatments for cancer, degenerative disorders, immunotherapy and stem cell transplantation. Cytotherapy publishes cutting edge findings, clinical trials of cell-based therapies, and news and opinion on all aspects of these disciplines. The journal focuses especially on the practical translation of scientific developments in the laboratory into clinical practice. Cytotherapy is an essential global resource for clinical researchers, oncologists, hematologists, doctors, and regulatory experts involved in cell processing and therapy.

Senior Editor of Cytotherapy, John Barrett, MD, commented, "What matters is ensuring that new peer-reviewed treatments, developments, and studies reach as many specialists working with cell therapies as possible. In this, I believe Elsevier offers an unrivaled opportunity to help the journal achieve this goal."

Glen Campbell, Executive Vice President at Elsevier added, "Cytotherapy is an established and reputable journal and we are honored that the International Society for Cellular Therapy selected Elsevier as their publishing partner. Together, we will ensure that this prestigious title develops further as the leading global forum and resource for developing and supporting innovative cellular therapies."

For more information go to: http://www.journals.elsevier.com/cytotherapy

About ISCT

ISCT is a global association driving the translation of scientific research to deliver innovative cellular therapies to patients. Since 1992, ISCT has been the leading global forum for developing and supporting innovative cellular therapies through communication, education and training. ISCT fosters international translational research, informs national and global regulatory framework development and harmonization, drives commercialization strategies, and educates principal investigators, lab directors, technologists, regulators and commercial stakeholders. http://www.celltherapysociety.org

Read more from the original source:
Elsevier Selected to Publish Cytotherapy: The Journal of Cell Therapy

SUNRISE, Fla., Jan. 7, 2013 /PRNewswire/ --Bioheart, Inc. (BHRT.QB) will present an update on 12 years of clinical data on MyoCell for treating heart failure at the 8th Annual Conference on Cell Therapy for Cardiovascular Disease January 23-25th, 2013 @ Columbia University Medical Center - http://celltherapy.crf.org/register.html - Course Director, Warren Sherman, M.D.

(Logo: http://photos.prnewswire.com/prnh/20130107/FL37699LOGO )

Howard J. Leonhardt, Founder and Chief Technology Officer of Bioheart, will present data from clinical trials sponsored by the company since 2001.

In Phase II/III clinical trials stage in the U.S. for muscle stem cells for treating advanced heart failure, Bioheart's MyoCell is believed to be the only cell type able to create new contractile muscle in heart scar tissue.Phase II/III Part I interim results demonstrated 95.7 meters improvement in exercise capacity in Bioheart MyoCell patients over placebo (-4 meters) in a double blind randomized study.This compares to -4 meters for CHF drugs, 16 meters for CRT pacers, 53 meters for cardiac stem cells, 52 meters for adipose derived cells and 10 meters allogeneic bone marrow derived cells.

Leonhardt will also provide a look at new generation improvements brought forward to enhance cell transplantation by Bioheart which include:SDF-1 gene transfection, electrical stimulation see http://www.myostimpacers.com, repeat injections, and nutrient hydrogel.

Founded in 1999, Bioheart is one of the original cell therapy companies.Since that time, more than 400 heart failure patients have been enrolled in various myoblast therapy clinical trials worldwide. 84% percent of Bioheart MyoCell treated patients have improved while only 16% have worsened. In placebo and control groups 69% of patients have worsened.

130 more patients are needed to complete the randomized, double blinded, placebo controlled MARVEL trial.MyoCell is a muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the intended purpose of improving cardiac function and quality of life in chronic heart failure patients.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

View original post here:
Bioheart to Present at Cell Therapy for Cardiovascular Disease Conference in New York

Genetic Engineering and the GMO Industry: Corporate Hijacking of Food and ... Center for Research on Globalization “I recognized my two selves: a crusading idealist and a cold, granitic believer in the law of the jungle” – Edgar Monsanto Queeny, Monsanto chairman, 1943-63, “The Spirit of Enterprise”, 1934. When rich companies with politically-connected lobbyists ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHBpIWB0F14kM2lOuK2nNBgP8ZF1g&url=http://www.globalresearch.ca/genetic-engineering-and-the-gmo-industry-corporate-hijacking-of-food-and-agriiculture/5317339

Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as ... PR Newswire (press release) Ms. Allen offers 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. For the past two years, she has provided independent consulting services to biotechnology companies in a variety ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFR9lc9-ACcxEG1QPGzCLM_NGj2cQ&url=http://www.prnewswire.com/news-releases/zafgen-appoints-20-year-biotechnology-industry-veteran-patricia-allen-cpa-as-chief-financial-officer-185643452.html

Market Report, "Tamir Biotechnology, Inc. - Product Pipeline Review - 2012 ... SBWire (press release) This report is built using data and information sourced from Global Markets Direct's proprietary databases, Tamir Biotechnology, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Tamir Biotechnology ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEk0M23cyudgIHQDO_0jadkUz7gJg&url=http://www.sbwire.com/press-releases/market-report-tamir-biotechnology-inc-product-pipeline-review-2012-published-191286.htm

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

Presents at cell biology gathering The Sunday Dispatch Yurko hopes to earn a Ph.D. in biochemistry and molecular genetics and plans a career in biomedical research specializing in autoimmune and multi-drug resistant diseases. “I have found a way I can help people. It took me a while, but I now know it is ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGSShwKBPJtIH1sY5yg44TSjlIxHg&url=http://psdispatch.com/stories/Presents-at-cell-biology-gathering,248167?category_id%3D29%26town_id%3D4%26sub_type%3Dstories

Stem Cell Therapy for Autism, Mumbai, India

By: Rajeev Ranjan

View original post here:
Stem Cell Therapy for Autism, Mumbai, India - Video